Related Experiment Videos

Autoradiographic studies on the distribution of 3H-2,3,4-trimethoxy-beta-phenylethylamine in the mouse

Psychopharmacologia
|January 1, 1976
PubMed

Insights

This study compared the distribution of 3H-2,3,4-trimethoxy-beta-phenylethylamine (2,3,4,-TMPEA), a mescaline isomer, in mouse organs. While similar to mescaline initially, 2,3,4,-TMPEA showed a more homogenous brain distribution over time.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Radiochemistry

Background:

  • Mescaline, a psychoactive compound, has a known distribution pattern in the brain and organs.
  • 2,3,4-trimethoxy-beta-phenylethylamine (2,3,4,-TMPEA) is a nonhallucinogenic structural isomer of mescaline.

Purpose of the Study:

  • To investigate and compare the regional distribution of radioactivity of 3H-2,3,4,-TMPEA with 3H-mescaline in mouse brain and other organs.
  • To understand the metabolic fate and tissue uptake differences between mescaline and its nonhallucinogenic isomer.

Main Methods:

  • Light microscopic autoradiography was employed to visualize the distribution of radiolabeled compounds.
  • Mice were injected with either 3H-2,3,4,-TMPEA or 3H-mescaline.
  • Radioactivity patterns were analyzed in brain, kidney, pancreas, adrenal glands, and spinal ganglia at various time points.

Main Results:

  • At 1 hour post-injection, 3H-2,3,4,-TMPEA exhibited a brain distribution pattern similar to 3H-mescaline.
  • Unlike mescaline, 3H-2,3,4,-TMPEA showed an increasingly homogenous distribution in the brain over time.
  • The distribution of 3H-2,3,4,-TMPEA in peripheral organs (kidney, pancreas, adrenal, spinal ganglia) differed significantly from that of 3H-mescaline.

Conclusions:

  • Despite rapid deamination, 2,3,4,-TMPEA initially shares brain distribution characteristics with mescaline.
  • The temporal dynamics of brain distribution differ between mescaline and 2,3,4,-TMPEA, suggesting distinct metabolic or transport mechanisms.
  • Peripheral organ distribution also diverges, highlighting unique pharmacokinetic properties of the nonhallucinogenic isomer.

Related Concept Videos